Initial drug therapy is effective in Japanese cedar pollinosis. However, some patients cannot take medications because they are ineffective, undesirable or have serious side effects. These patients choose treatments such as immunotherapy or surgical intervention. Although allergic rhinitis is not lethal, it can decrease the quality of life (QOL) with sudden short-term aggravation, such as that caused by Japanese cedar pollinosis. To assess allergic rhinitis therapy objectively, we studied the difference in the effects of subcutaneous immunotherapy (SCIT) and initial drug therapy using a visual analogue scale (VAS) to assess symptoms and a QOL questionnaire. This study enrolled patients who were examined during the cedar pollen season in 2011 and divided them into three groups: the immunotherapy, initial drug therapy, and after onset groups. The results showed that SCIT had marked effects on symptoms such as sneezing, nasal discharge, eye itching, and lacrimation via an antihistaminic action and improved the QOL, including daily life, outdoor activities, and spiritual life during the pollen season. Due to its efficacy for both treatment of the symptoms and improvement of the QOL of our patients, we plan to continue to promote SCIT.